Tower Research Capital LLC TRC Acquires 10,185 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Tower Research Capital LLC TRC lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 95.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,891 shares of the biopharmaceutical company’s stock after purchasing an additional 10,185 shares during the period. Tower Research Capital LLC TRC’s holdings in Celldex Therapeutics were worth $528,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CLDX. Vanguard Group Inc. boosted its stake in shares of Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after acquiring an additional 12,213 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Celldex Therapeutics by 46.5% during the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock worth $15,376,000 after acquiring an additional 193,093 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Celldex Therapeutics by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock worth $13,755,000 after acquiring an additional 5,474 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Celldex Therapeutics by 20.9% in the fourth quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company’s stock worth $11,435,000 after buying an additional 78,145 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Celldex Therapeutics by 9.6% during the 4th quarter. Barclays PLC now owns 142,914 shares of the biopharmaceutical company’s stock worth $3,611,000 after buying an additional 12,533 shares during the period.

Celldex Therapeutics Trading Up 9.1 %

Shares of CLDX stock opened at $21.36 on Tuesday. The stock has a 50 day moving average of $19.18 and a two-hundred day moving average of $23.37. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The company has a market capitalization of $1.42 billion, a P/E ratio of -8.31 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CLDX. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. Morgan Stanley assumed coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Finally, UBS Group assumed coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.30.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.